PSM

CME

Controversies in Management of Colorectal Peritoneal Carcinomatosis

Moderator(s)

• 

  Alexandra Gangi, M.D.

  Attending
  Cedars-Sinai Medical Center
  Los Angeles, California, United States

  Disclosure(s): No financial relationships to disclose
• 

  Jeremiah Deneve, DO (he/him/his)

  Associate Professor of Surgery
  University of North Carolina at Chapel Hill
  Chapel Hill, North Carolina, United States

  Disclosure(s): No financial relationships to disclose

Role of CRS/HIPEC metastatic colorectal cancer: Role of Neoadjuvant therapy for limited disease volume, Intraoperative Chemotherapy Consideration, Optimal surveillance and follow up, Emerging role of ctDNA in patient selection.

Presentations:

• 9:45am – 9:57am ET

  Role of Neoadjuvant Therapy: Who and How Much?
  

  Presenter: Prakash K. Pandalai, MD (he/him/his) – Division of Surgical Oncology, Department of Surgery, University of Kentucky
• 9:57am – 10:08am ET

  Intraoperative Chemotherapy Consideration for Colorectal Cancer
  

  Presenter: Maria Citarella Russell, MD – Emory University
• 10:08am – 10:20am ET

  Optimal Follow up – Role of ctDNA
  

  Presenter: Anai Kothari, MD, MS – Medical College of Wisconsin
• 10:20am – 10:32am ET

  Optimal Tumor Burden for CRS/HIPEC in Colorectal Cancer
  

  Presenter: Sean Dineen, MD – Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States
• 10:32am – 10:45am ET

  Q & A/Discussion